Murchinson’s Biogen BIIB Stock Holding History

Murchinson’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-25,000	Closed	-$6.67M	–	48
2022 Q3	$6.67M	Sell	25,000 -25,000	-50%	-$5.31M	1.93%	10
2022 Q2	$10.2M	Buy	50,000 +5,000	+11%	+$1.02M	1.95%	7
2022 Q1	$9.48M	Buy	45,000 +25,000	+125%	+$5.44M	1.81%	7
2021 Q4	$4.8M	Hold	20,000	–	–	0.46%	24
2021 Q3	$5.66M	Buy	20,000 +5,000	+33%	+$1.64M	2.81%	12
2021 Q2	$5.19M	Buy	+15,000	New	+$4.54M	1.87%	15

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Murchinson's BIIB Position: Q4 2022 in Review

Murchinson sold out of Biogen (BIIB) in Q4 2022, closing a stake of 25,000 shares — an estimated $6.67M sold.

Murchinson first reported a position in BIIB in Q2 2021 and held it in 6 quarters. The position peaked at $10.2M in Q2 2022. 1,031 funds tracked by Wall St. Rank hold BIIB as of Q4 2022.

Murchinson reported no remaining Biogen position as of Q4 2022 after selling out during the quarter.
Murchinson sold 25,000 Biogen shares in Q4 2022, an estimated $6.67M.
Murchinson first reported a position in Biogen in Q2 2021 and held it in 6 quarters.
Murchinson's Biogen position peaked at $10.2M in Q2 2022.
1,031 funds tracked by Wall St. Rank held Biogen as of Q4 2022.

Based on Murchinson's 13F filing for Q4 2022, filed 10 Feb 2023.